News

Unicycive Therapeutics Engages Investors with Upcoming Events

Unicycive Therapeutics Engages Investors with Upcoming Events

Introduction to Unicycive Therapeutics

Unicycive Therapeutics, Inc. (NASDAQ: UNCY) is an innovative biotechnology firm based in Los Altos, California, dedicated to developing cutting-edge therapies for individuals with kidney diseases. The company is currently making strides in its research and has announced significant participation in upcoming investor events.

Upcoming Investor Events

The company's Chief Executive Officer, Shalabh Gupta, M.D., is set to engage with investors through two significant events in the upcoming December. These events aim to provide insights into Unicycive’s current and future strategies.

Piper Sandler Annual Healthcare Conference

The first event, the Piper Sandler 37th Annual Healthcare Conference, will take place on December 3, 2025, at 10:00 a.m. ET. During this fireside chat, Dr. Gupta will share critical updates about the company's progress, innovations, and strategic plans in the realm of kidney disease treatments.

Noble Capital Markets Virtual Presentation

Following the Piper Sandler event, Unicycive Therapeutics will participate in a virtual presentation hosted by Noble Capital Markets on December 10, 2025, at 10:00 a.m. PT. This session promises to offer valuable insights and is an excellent opportunity for stakeholders to learn more about the company's ongoing research and development efforts.

Innovative Treatments for Kidney Diseases

Unicycive leads with its investigational product, oxylanthanum carbonate. This new phosphate-binding agent is currently undergoing review by the U.S. Food and Drug Administration (FDA) for treating hyperphosphatemia in patients with chronic kidney disease on dialysis. This innovative approach reshapes the treatment paradigm for these patients, promising a better quality of life.

Second Investigational Treatment: UNI-494

Additionally, Unicycive Therapeutics is advancing another significant project, UNI-494, tailored for treating conditions connected to acute kidney injury. Impressively, UNI-494 has received orphan drug designation (ODD) by the FDA, aimed at delaying graft function in kidney transplant recipients, and has successfully completed a Phase 1 safety study. These developments mark a meaningful progression in addressing the urgent needs within kidney healthcare.

Engagement and Access to Information

For further information about the live and archived webcasts of the Piper Sandler conference and the Noble presentation, interested parties can visit the Investors section of Unicycive’s website. This access is designed to keep investors informed about the company's evolving landscape and performance.

About Unicycive Therapeutics

With a mission to innovate, Unicycive Therapeutics looks to leverage its groundbreaking research to benefit those affected by kidney diseases. The company harnesses scientific advancements to design therapies that truly make a difference in patient care and management.

Conclusion

As Unicycive Therapeutics continues to make remarkable advancements in the biotechnology field, its engagement in upcoming investor events presents promising opportunities for stakeholders. The outlook for the company appears bright, with potentially transformative treatments like oxylanthanum carbonate and UNI-494 on the horizon.

Frequently Asked Questions

What is Unicycive Therapeutics known for?

Unicycive Therapeutics is recognized for developing innovative therapies targeting kidney diseases, including investigational treatments for chronic kidney disease and acute kidney injury.

When are the upcoming investor events?

The investor events are scheduled for December 3 and December 10, 2025, where the CEO will present insights about the company.

What is oxylanthanum carbonate?

Oxylanthanum carbonate is Unicycive's lead investigational therapy, designed as a phosphate-binding agent for patients with hyperphosphatemia.

What does orphan drug designation mean?

This designation is given by the FDA to encourage the development of drugs for rare diseases, providing incentives for companies to invest in these treatments.

How can I follow Unicycive Therapeutics' updates?

You can stay informed by visiting their official website and following their updates across social media platforms.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Data Centers: More Power-Hungry Than Thirsty

Updated Category News Views 134

Data Centers: Not Quite the Water Guzzlers We Feared Hold onto your hats, because the latest intel on data centers is changing the game, or at least forcing a closer look at what seems like a done deal. The big reveal? It's not the water, folks—it’s the juice. While everyone frets about water, electricity is the silent giant you’ve got to wrangle. Water vs....

Continue Reading
Fitness Career Platform's Big Ramp Up Sparks Buzz

Updated Category News Views 116

ISSA Career Connect Gains Industry Recognition In a world where finding that first job post-certification can be as brutal as a spin class in August, ISSA Career Connect seems to be offering a bit of a lifeline. This platform, already making some serious noise in the fitness industry, has just snagged a place as a finalist for App of the Year at the 2026 Beyond Activ...

Continue Reading
Shorr Packaging's Sustainable Edge: EcoVadis Silver Triumph

Updated Category News Views 119

EcoVadis Silver Badge: Shorr's Green Path Imagine this: Shorr Packaging strutting around with an EcoVadis Silver Badge pinned to its chest for not one, not two, but three years now. That's right, Shorr Packaging's been elbowing its way to the top tier with their sustainability drive, ranked in the 93rd percentile. For those not keeping score, that's top-notch, considering...

Continue Reading
Monotype's Inkwell: A Type Family with New Twists

Updated Category News Views 72

Fresh Faces in the World of Type Out of the design trenches comes news that Monotype—the big cheese in type and tech—just rolled out four new styles in its well-liked Inkwell lineup. We're talking Inkwell Antique, Formal, Chancery, and Ornaments here. The idea? Give designers more room to play with tone. Let's chew on what this expansion means for folks rocking...

Continue Reading
WeFetch AI: A New Era in Barcode Precision

Updated Category News Views 80

WeFetch AI: What's in a Name? Forget about GreenCore Solutions Corp. We're talking about WeFetch AI Corp. now. They've just changed their name, fulfilling a bureaucratic tick as of November 13, 2026. But it ain't just a name change; it's a whole new ballgame in AI-driven commerce. AI Shopping Without the Guesswork We've all been there. You think you've ordered that...

Continue Reading
Biointron's RushDATA™: Speeding Up Antibody Discovery

Updated Category News Views 150

A New Chapter in Antibody Discovery Well, color me intrigued. Biointron, a name you'd recognize if you've got even a toe in the biotech pond, just threw a serious curveball into the antibody discovery game with RushDATA™—an AI- and machine learning-driven platform that's packing a punch. And it's not just about throwing tech buzzwords around; this thing clocks...

Continue Reading
Innovative Rotating Kitchen Organizer Up for Licensing

Updated Category News Views 76

Dusting Off the Corners: A Fresh Spin on Kitchen Storage Just when you think there's nothing new under the sun when it comes to storing your kitchen gadgets, here comes an invention straight out of Billings, Montana. It's called The Rotating Kitchen Organizer, a nifty contraption that's all set to turn those dead corners into prime real estate. How many times have we...

Continue Reading
Greenberg Traurig's Brad Kaufman: A Mentor of Resolute Impact

Updated Category News Views 178

A Milestone for Mentorship at Greenberg Traurig In the often cutthroat jungle of law, finding someone who actually gives a damn about you is as rare as finding a unicorn. Yet, there it is—Brad Kaufman, at the helm of Greenberg Traurig's professional development, proving that mentorship can be more than just a checkbox on a quarterly review. Award for Exceptional...

Continue Reading
Business Boom in 2026: Key Regions to Watch Now

Updated Category News Views 114

Business Formations Break Records in 2026 I'm telling you, the entrepreneurial spirit is alive and kicking across the States this year. The latest numbers from Registered Agents Inc are clear as day: business is bustling. We're looking at 576,818 new business setups nationwide just in October 2026. That's outpacing the previous year by a whopping 8%. And if that doesn't...

Continue Reading
$10,000 Boost Fuels Nichols College's Archaeological Quest

Updated Category News Views 155

Webster First's Generous Contribution It's not every day you see a credit union digging into history—literally. Webster First Federal Credit Union just dropped ten grand to fuel Nichols College's archaeological adventures. This isn't some trivial check to post on Instagram. No, we're talking about funding some serious ground-penetrating radar (GPR) gadgetry that's set...

Continue Reading

Top 5 Most Recently Viewed Articles

Milberg Advances Legal Battle Against Big Oil's Deception

Updated Category News Views 404

Milberg's Lawsuit Against Fossil Fuel Giants In a significant development for climate justice, a federal magistrate judge has made a ruling that allows the crucial lawsuit initiated by municipalities in Puerto Rico against major fossil fuel companies to move ahead. This legal battle is founded on the Racketeer Influenced and Corrupt Organizations Act (RICO) and aims to...

Continue Reading
Investors of MGP Ingredients, Inc. Explore Legal Action Options

Updated Category News Views 100

Investors of MGP Ingredients, Inc. Explore Legal Action Options MGP Ingredients, Inc. (MGPI) offers an important opportunity for investors who faced losses due to securities fraud. In light of recent events, affected shareholders are urged to take action and consider leading a class action lawsuit. This situation underscores the importance of staying informed about your...

Continue Reading
Dialysis Market Growth Driven by Chronic Kidney Disease Rise

Updated Category News Views 72

Overview of the Dialysis Market Growth The healthcare landscape is witnessing a notable increase in the demand for dialysis, which is expected to grow at a compound annual growth rate (CAGR) of 7.7% over the next few years. This growth is primarily driven by the rising number of diabetes and hypertension cases across the globe. With a stronger emphasis on managing chronic...

Continue Reading
Pollen Street Group Welcomes Crispin Goldsmith as CFO

Updated Category News Views 208

Pollen Street Group Welcomes New Chief Financial Officer Pollen Street Group Limited has made a significant move by appointing Crispin Goldsmith as its new Chief Financial Officer (CFO). This appointment reflects the company's commitment to strengthening its leadership team and enhancing its strategic direction. Goldsmith's Extensive Experience Crispin Goldsmith is no...

Continue Reading
Celebrating Probiotic Innovation: Join the 30-Day Gut Challenge

Updated Category News Views 147

Celebrating 30 Years of Probiotic Innovation Bio-K+, a leader in probiotic healthcare, is thrilled to announce the launch of its 30-Day Gut Challenge. This exciting initiative marks the brand's significant milestone of 30 years devoted to advancing gut health through scientific research. The campaign encourages individuals to embrace healthier daily practices and...

Continue Reading